PRIMARY STUDY
Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy.
Key Findings: 'Peripheral' CB1R blockade is beneficial in experimental DN and this effect is synergically magnified by CB2R activation.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): Italy, United States
Year of Pub: 2017
Cannabinoids Studied: AM-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Citation: Barutta F, et al. Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. Nephrol Dial Transplant. 2017; 32:1655-1665. doi: 10.1093/ndt/gfx010
Authors: Barutta F, Grimaldi S, Gambino R, Vemuri K, Makriyannis A, Annaratone L, di Marzo V, Bruno G, Gruden G
